Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.
- "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
- "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
- Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
- Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.